Inhibition of sirtuins has recently been proposed as a promising anticancer strategy. Some of the new benzodeazaoxaflavins (2a, 2b, and 2d) here reported as SIRT1/2 inhibitors were endowed with pro-apoptotic properties in human U937 leukemia cells and, most importantly, together with the prototype MC2141 (1) displayed antiproliferative effects in cancer stem cells from patients with colorectal carcinoma and glioblastoma multiforme, known to be highly tumorigenic, resistant to conventional cancer chemotherapy, and responsible, at least in part, for cancer relapse or recurrence.

Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells / Rotili, Dante; Tarantino, D; Carafa, V; Paolini, C; Schemies, J; Jung, M; Botta, G; Di Maro, S; Novellino, E; Steinkühler, C; De Maria, R; Gallinari, P; Altucci, L; Mai, Antonello. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 55:(2012), pp. 8193-8197. [10.1021/jm301115r]

Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells.

ROTILI, Dante;MAI, Antonello
2012

Abstract

Inhibition of sirtuins has recently been proposed as a promising anticancer strategy. Some of the new benzodeazaoxaflavins (2a, 2b, and 2d) here reported as SIRT1/2 inhibitors were endowed with pro-apoptotic properties in human U937 leukemia cells and, most importantly, together with the prototype MC2141 (1) displayed antiproliferative effects in cancer stem cells from patients with colorectal carcinoma and glioblastoma multiforme, known to be highly tumorigenic, resistant to conventional cancer chemotherapy, and responsible, at least in part, for cancer relapse or recurrence.
2012
01 Pubblicazione su rivista::01a Articolo in rivista
Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells / Rotili, Dante; Tarantino, D; Carafa, V; Paolini, C; Schemies, J; Jung, M; Botta, G; Di Maro, S; Novellino, E; Steinkühler, C; De Maria, R; Gallinari, P; Altucci, L; Mai, Antonello. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 55:(2012), pp. 8193-8197. [10.1021/jm301115r]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/485200
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact